Who are NETILDEX™ ophthalmic gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tobramycin and dexamethasone ophthalmic suspension, Tobramycin and dexamethasone, NETILDEX™ eye drops solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/netildex-ophthalmic-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

NETILDEX™ ophthalmic gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NETILDEX™ ophthalmic gel (NETILDEX™ ophthalmic gel) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic/corticosteroid combination. Area: Ophthalmology.

phase 3 Antibiotic/corticosteroid combination Bacterial 30S ribosomal subunit (netilmicin); glucocorticoid receptor (dexamethasone) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

NETILDEX™ ophthalmic gel (NETILDEX™ ophthalmic gel) — SIFI SpA. NETILDEX is a combination ophthalmic gel containing netilmicin (an aminoglycoside antibiotic) and dexamethasone (a corticosteroid) that reduces bacterial infection and inflammation in the eye.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NETILDEX™ ophthalmic gel TARGET	NETILDEX™ ophthalmic gel	SIFI SpA	phase 3	Antibiotic/corticosteroid combination	Bacterial 30S ribosomal subunit (netilmicin); glucocorticoid receptor (dexamethasone)
Tobramycin and dexamethasone ophthalmic suspension	Tobramycin and dexamethasone ophthalmic suspension	Bausch & Lomb Incorporated	marketed	Antibiotic/corticosteroid combination	Bacterial ribosome (tobramycin); glucocorticoid receptor (dexamethasone)
Tobramycin and dexamethasone	Tobramycin and dexamethasone	Bausch & Lomb Incorporated	marketed	Antibiotic/corticosteroid combination	Bacterial ribosome (tobramycin); glucocorticoid receptor (dexamethasone)
NETILDEX™ eye drops solution	NETILDEX™ eye drops solution	SIFI SpA	phase 3	Antibiotic/corticosteroid combination	Bacterial 30S ribosome (netilmicin); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic/corticosteroid combination class)

Bausch & Lomb Incorporated · 2 drugs in this class
SIFI SpA · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NETILDEX™ ophthalmic gel — Competitive Intelligence Brief. https://druglandscape.com/ci/netildex-ophthalmic-gel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab